KLOR-CON M15 (potassium chloride)
KLOR-CON M15 is indicated for the treatment of Hypokalemia; Metabolic Alkalosis.
How KLOR-CON M15 Works
Potassium chloride provides potassium, the primary intracellular cation in most body tissues. It is essential for maintaining intracellular tonicity and the transmission of nerve impulses. Potassium ions are critical for the contraction of cardiac, skeletal, and smooth muscle, as well as the maintenance of normal renal function. The medication helps maintain the necessary concentration gradient between intracellular and extracellular compartments, which is normally regulated by an active ion transport system.
Details
- Status
- Prescription
- First Approved
- 1998-11-20
- Routes
- ORAL
- Dosage Forms
- TABLET, EXTENDED RELEASE
KLOR-CON M15 Approval History
What KLOR-CON M15 Treats
2 indicationsKLOR-CON M15 is approved for 2 conditions since its original approval in 1998. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Hypokalemia
- Metabolic Alkalosis
KLOR-CON M15 Competitive Set
ProThree rings of competition based on shared molecular targets and treated indications.
Indication competitors
Same indication, different mechanism — what else might this patient receive?
Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.
Drugs Similar to KLOR-CON M15
3 of 20FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Clinical Trial Registry
8 trials| Trial | Sponsor ID | Phase | Status | Title |
|---|---|---|---|---|
| NCT07238400 CARDAMOM | 2025P001799 R01HL181150 | Ph 2 | recruiting | Cardiac Effects of Mineralocorticoid Receptor Antagonism After Preeclampsia |
| NCT04316611 POTACREH | APHP180577 2019-002544-24 | Ph 2 | withdrawn | Potassium Chloride in Out-of-hospital Cardiac Arrest Due to Refractory Ventricular Fibrillation |
| NCT02450773 | 201501157 | Ph 2 | withdrawn | Prevention of Severe Postpartum Hypertension |
| NCT03627130 NITRATE-CIN | 18/1 | Ph 2 | completed | The Use of Inorganic Nitrate for the Prevention of Contrast-induced Nephropathy |
| NCT03483051 PULSE-AS results posted | 828994 | Ph 2 | completed | Targeting Pulsatile Load to Increase Exercise Capacity and Quality of Life After Aortic Valve Replacement for Severe Aortic Stenosis (PULSE AS) |
| NCT01074918 | 012007-080 | Ph 1, Ph 2 | withdrawn | Potassium-Magnesium Citrate as a Blood Pressure Lowering Agent in Hypertensive Patients |
| NCT01818583 | AK-01 | Ph 4 | completed | Potassium Infusion for Conversion of Atrial Fibrillation/-Flutter |
| NCT01085071 GRIP-COMPASS | GRIP-COMPASS trial | Ph 4 | completed | Comparison of Two Potassium Targets Within the Normal Range in Intensive Care Patients |
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
KLOR-CON M15 FDA Label Details
Indications & Usage
FDA Label (PDF)KLOR-CON M15 is indicated for the treatment of Hypokalemia; Metabolic Alkalosis.
Track KLOR-CON M15 with TheraRadar Pro
Watchlist alerts, full database access, CSV exports across 14,000+ drugs.
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.